Embargoed for 9am CET (3am ET) on Monday November 3rdAmgen Ventures-backed AAVantgarde Bio has raised $143 million in series ...
Will Lewis, Insmed CEO, joins 'Fast Money' to talk Insmed's rare gene therapy development, demand, and quarterly results.
In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...
In a major setback, Uniqure said that the timing of when it can file its Huntington's treatment for FDA approval "is now ...
In 1962, a pediatric neurology resident at Columbia's Neurological Institute and his colleagues in the College of Physicians ...
The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...
The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the treatment being hailed as a game-changer. | FDA is said to be making a U-turn on ...
In the spring of 2024, the US Food and Drug Administration (FDA) approved fidanacogene elaparvovec (Beqvez), only the second gene therapy product for hemophilia B. Just a few months later, the Pfizer ...
Oncologists' experience with CGT has increased, with more patients treated and earlier lines of therapy being utilized.
Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not ...
In honor of World Blindness Awareness Month, "GMA" is spotlighting a breakthrough gene therapy that's helping some blind ...
With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback